Souhaitez-vous accéder aux communiqués récents ?

Oblenio's Series B round was led by Pfizer Ventures, with participation from new investors Deep Track Capital, GV, and founding investor, Aditum Bio.

Austin, TX, USA, June 25, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “Therapeutic Apheresis Market Size, Trends and Insights By Product Type (Apheresis...

Novel immune reprogramming oral macrocyclic peptides designed for precise modulation of complex biological networks involved in inflammatory, autoimmune and fibro-inflammatory diseases Company...

Phase 1b clinical trial of SYX-5219 in adults with moderate to severe atopic dermatitis completes enrollment ahead of scheduleRapid progress in the United States and Europe reflects strong...

Arthritis and other adverse musculoskeletal effects of COVID-19 vaccines could cause enormous disability. Needed research requires restoration of academia

Oxford, UK and Boston, MA – May 18, 2026 – Sitryx Therapeutics (“the Company”), a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and...

Planned Interim Futility Analysis from Pivotal Phase 2 ALPHA3 Trial Supports Cemacabtagene Ansegedleucel’s (Cema-Cel) Potential as an Outpatient, MRD-Guided Consolidation Therapy in 1L Large B-cell...

First-in-human healthy volunteers trial showed SYX-5219 was safe and well toleratedSystemic immunomodulation of type 2 inflammation demonstrated with reduction in serum CCL17/TARC Phase 1b trial in...

Anaveon appoints Thomas P. Mathers as Chair of the Board of Directors.

Alira Health, in partnership with the Autoimmune Neurology Alliance (AiNA), today announced the launch of the AXIS Registry.